Research programme: cancer diagnostics and therapeutics - Cellectar Biosciences

Drug Profile

Research programme: cancer diagnostics and therapeutics - Cellectar Biosciences

Alternative Names: 127I-CLR 1404; CLR 125; CLR 127; CLR 1401-boron-dipyrromethene analog; CLR 1404; CLR 1500 compounds - Cellectar Biosciences; CLR 1502; CLR 1601 PTX; CLR 1602; CLR 1602-PTX; CLR 1603; CLR 1603-PTX; CLR 1605-GEM; CLR 1700 series; CLR 1800 series; CLR 1900 series; CLR 2000 series; CLR 2100 series; CLR 2200 series; CLR CTX; CLR1401; CLR1501; CLR1505; COLD; GLOW1; GLOW2; PDCs - Cellectar Biosciences; Phospholipid drug conjugates - Cellectar Biosciences; Phospholipid ether analogues - Cellectar Biosciences; PLEs - Cellectar Biosciences

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Michigan Medical School
  • Developer Cellectar Biosciences
  • Class Drug conjugates; Imaging agents; Phospholipids; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Apoptosis modulators; CD244 antigen modulators; CD8 positive T lymphocyte modulators; Cell division modulators; DNA synthesis inhibitors; Gene modulators; Histone deacetylase inhibitors; Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer
  • No development reported Solid tumours

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for preclinical development in Cancer in USA (IV)
  • 28 Jul 2018 No recent reports of development identified for preclinical development in Solid-tumours(Diagnosis) in USA (IV)
  • 27 Mar 2018 Cellectar Biosciences has patent protection for Phospholipid-ether analogs in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top